SEC Form 4 · accession 0001104659-26-103374
Quoin Pharmaceuticals, Ltd. · QNRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony James Culverwell
Director
Period of report
Aug 27, 2026
Accepted (ET)
Aug 28, 2026 · 6:39 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001671502
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ADSsF1 | Aug 27, 2026 | A | 31,352 | $5.15 | A | 34,218 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
- F2On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $161,461 of accrued interest outstanding ("Outstanding Debt") owed in connection with a note previously purchased by the Reporting Person was exchanged for 31,352 ADSs. The exchange agreement and the exchange of the Outstanding Debt for the ADSs was approved in advance by the Issuer's audit committee and board of directors.